2014 News Releases

Webcast ImageWebcast
Q2 2014 InterMune Earnings Conference Call (Replay)
08/06/14 at 1:30 p.m. PT
Keyword Search
Submit
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
08/24/14Roche and InterMune Reach Definitive Merger Agreement
-- Roche to acquire InterMune for $74.00 per share -- -- InterMune's lead product pirfenidone for idiopathic pulmonary fibrosis to expand Roche's respiratory product portfolio -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction.  This corresponds to a t... 
Printer Friendly Version
08/06/14InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
-- Transformational H1 2014 includes presentation of Phase 3 ASCEND data, NDA resubmission and target PDUFA date of Nov. 23 for pirfenidone in U.S. - -- Reports Esbriet® revenue of $35.7 million in Q2 2014 - BRISBANE, Calif., Aug. 6, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter ended June 30, 2014.  The company also highlighted recent clinical development and business highlights, and updated its forward-looking financial... 
Printer Friendly Version
07/28/14InterMune to Release Second Quarter Financial Results on August 6
BRISBANE, Calif., July 28, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S. markets on Wednesday, August 6, 2014. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. Interested investors and others may participate in the conference call by dialing 800-728-2056 (U.S.) or +1 212-231-2900 (international), conference ID#21728775. A replay o... 
Printer Friendly Version
07/17/14InterMune Receives FDA Breakthrough Therapy Designation for Pirfenidone, an Investigational Treatment for IPF
BRISBANE, Calif., July 17, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA).  This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant ... 
Printer Friendly Version
05/27/14InterMune Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF
BRISBANE, Calif., May 27, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010.  Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). "We are pleased to have resubmitted the pirfenidone NDA and look forward to our interactions with the FDA... 
Printer Friendly Version
05/20/14InterMune Announces Additional Pirfenidone Data in Idiopathic Pulmonary Fibrosis
- Pooled Efficacy Analyses from Phase 3 ASCEND and CAPACITY Studies Presented at 2014 American Thoracic Society Meeting - - Long-term Safety Outcomes Published in the Journal of Respirology - - Investor Conference Call and Webcast Today at 8 p.m. EDT (5 p.m. PDT) - SAN DIEGO, May 20, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that results of analyses of pooled data from the ASCEND trial and the two previous Phase 3 CAPACITY trials evaluating pirfenidone in patie... 
Printer Friendly Version
05/18/14Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine
- Investor Conference Call and Webcast Today at 8 p.m. EDT (5 p.m. PDT) - BRISBANE, Calif., May 18, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that results from the Phase 3 ASCEND study evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were presented today at the International Conference of the American Thoracic Society (ATS) in San Diego, and published on-line in the New England Journal of Medicine.  Dr. Talmadge King, Professor and Chai... 
Printer Friendly Version
05/16/14InterMune Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States
BRISBANE, Calif., May 16, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced it will provide compassionate use of pirfenidone through a multi-center Expanded Access Program (EAP) in the United States to be conducted under InterMune's U.S. IND.  Pirfenidone is an investigational therapy in the U.S. and has not been approved by the U.S. Food and Drug Administration (FDA). Expanded access programs provide a mechanism for early access to an investigational drug in the pre-approva... 
Printer Friendly Version
05/12/14InterMune Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting
-- Important New Data Reflecting Broad Pipeline in Fibrotic Diseases Will Be Presented -- -- Company to Host Live Webcasts on May 18 and 20 -- BRISBANE, Calif., May 12, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that several investigational molecules and data from studies of pirfenidone will be presented at the 2014 International Conference of the American Thoracic Society (ATS), May 16 – 21, in San Diego, Calif. in a total of 18 abstracts.  Updates on In... 
Printer Friendly Version
05/01/14InterMune Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights
BRISBANE, Calif., May 1, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2014.  The company also highlighted recent clinical development and business highlights, and raised its forward-looking revenue guidance for 2014.    InterMune reported Esbriet® (pirfenidone) revenue in the first quarter of 2014 of $30.3 million, compared with $10.5 million in the same quarter a year earlier, an increa... 
Printer Friendly Version
04/23/14InterMune To Release First Quarter Financial Results On May 1
BRISBANE, Calif., April 23, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2014 financial results at the close of the U.S. markets on Thursday, May 1, 2014. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. Interested investors and others may participate in the conference call by dialing 800-745-9476 (U.S.) or +1 212-231-2906 (international), conference ID#21714990. A repla... 
Printer Friendly Version
03/13/14InterMune Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
BRISBANE, Calif., March 13, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75 per share in an underwritten public offering.  InterMune has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering.  InterMune estimates net proceeds from the offering to be approximately $233.0 million (assuming no exerc... 
Printer Friendly Version
03/12/14InterMune Announces Proposed Public Offering of Common Stock
BRISBANE, Calif., March 12, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering.  The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering.  All of the shares in the offering will be sold by InterMune.  The shares will be issued pursuant to a pro... 
Printer Friendly Version
02/25/14InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
- Study Meets Primary and Both Key Secondary Endpoints - - Company to Conduct Conference Call and Webcast Today at 8:00 a.m. EST - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital... 
Printer Friendly Version
01/09/14InterMune Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue and Recent Business Highlights
- Q4'13 revenue of $25.6 million represents ninth consecutive quarter of Esbriet growth - - Last patient to complete treatment this month in Phase 3 ASCEND trial - - Strong progress on antifibrotic R&D pipeline - BRISBANE, Calif., Jan. 9, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited revenue for the fourth quarter and year ended December 31, 2013.  The company also provided updated 2013 expense guidance, highlighted recent progress in its commercial a... 
Printer Friendly Version
01/06/14InterMune to Present at J. P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 6, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 32nd Annual J. P. Morgan Healthcare Conference in San Francisco on January 13, 2014, at 12:00 Noon EST / 9:00 a.m. PST.  (Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) To access a live audio webcast of the presentation, investors and other interested parties may log on to the investo... 
Printer Friendly Version

You are now leaving the InterMune website. If you would like to continue, click Continue. Otherwise, click Cancel.
CancelContinue